OBJECTIVES: The objective of this study was to compare survival in patients with stage IIIA (N2) non-small-cell lung cancer (NSCLC) treated with definitive chemoradiation (CRT) or surgery plus neoadjuvant chemoradiation or chemotherapy (CRTS).
INTRODUCTION
Lung cancer remains the leading cause of cancer mortality among men and women worldwide. Patients who present with nonsmall-cell carcinoma of the lung with metastasis to the ipsilateral mediastinal lymph nodes (N2 disease) account for 10-15% of newly diagnosed cases [1] . Although prognosis for these patients is poor, survival outcomes are related to both the extent of N2 disease and the response to treatment [2] [3] [4] . The role of surgery in the management of patients with N2 disease is controversial as the current recommended standard for curative intent treatment is concurrent chemoradiotherapy [5] .
Stage IIIA N2 is a heterogeneous disease ranging from single station, microscopic N2 disease found on pathology to bulky multistation N2 nodes fixed to the airway and/or great vessels. The latter group of patients are not surgical candidates, whereas surgery may be considered for the former group. In addition to disease burden, patient comorbidities influence treatment decisions. Poor patient performance status may preclude curative intent therapy.
Previous phase III trials have been inconclusive in determining the role of surgical treatment of stage IIIAN2 NSCLC. The German phase III trial compared preoperative chemotherapy with chemoradiation (CRT) and found no difference in survival [6] . The Intergroup 0139 trial found that neoadjuvant CRT followed by surgery increased progression-free survival (PFS) but not overall survival in comparison with CRT alone. However, the overall survival (OS) in the surgical group of this trial was confounded by postoperative mortality particularly the high mortality rate following pneumonectomy [7] . As a result, the management strategy for stage IIIA (N2) disease remains controversial.
A previous review of patients with stage IIIA N2 NSCLC treated with neoadjuvant CRT followed by surgery at University Health Network reported a 3-year survival of 52%, which was superior to that reported in the 0139 trial but more importantly, there were no operative deaths in the latter part of the study [8] . This suggested that surgeons gained technical experience in operating after CRT but also that they may have been more selective in choosing candidates for surgery. Based on our previous experience, we wished to clarify whether neoadjuvant therapy followed by surgery offers any benefit over CRT alone. Hence, this study was designed to compare patients with stage IIIA N2 disease treated with curative intent by either CRT or neoadjuvant therapy plus surgery in our institution.
METHODS
From an existing database of 740 patients with stage III non-smallcell lung cancer treated at University Health Network between 1997 and 2007, 242 patients with stage IIIA (N2) NSCLC were treated with curative intent. Patients treated with CRT followed by surgery (91), chemotherapy followed by surgery (13) or definitive CRT (111) were included in this study. Patients treated with radical radiation alone and those treated with curative intent non-surgical therapy but who had unresectable disease based on review of pretreatment computerized tomography (CT) scans were excluded.
Radiological evaluation
Pretreatment chest CT scans were reviewed separately by two chest radiologists (Adam G. Wallis Demetris Patsios), who were blinded to the patients' treatment plan, to determine resectability, clinical stage, size and number of nodes at mediastinal nodal stations. One thoracic surgeon (G.D.) evaluated the CT scans to determine resectability from the surgical perspective. Patients with unresectable disease were excluded from the analysis even if they were treated with curative intent therapy (i.e. definitive CRT). Unresectable disease included tumours with mediastinal invasion, T4 tumours, bulky fixed mediastinal nodes with no visible tissue plane between nodes and trachea or encasement or invasion of the great vessels or heart. Patients with radiologically determined technically resectable stage IIIA N2 disease were included in the analysis. Tumours were further characterized as borderline resectable if a complex resection ( pulmonary artery sleeve, carinal, atrial or superior vena caval resection) may have been required. Also, tumours were categorized as likely to require pneumonectomy for resection versus lobectomy.
Lung cancer staging was determined according to the Union for International Cancer Control Tumor, Node Metastases (TNM) Classification of Malignant Tumors seventh edition [9] . The study was approved by the institutional research ethics board. The requirement for patient consent was waived.
Study design
The two treatment groups were analysed for overall survival (OS), disease-free survival (DFS), median survival, local regional and distant recurrences, treatment-related mortality. Although data on comorbidities were incomplete, Eastern Cooperative Oncology Group (ECOG) performance status was recorded for all patients. All patients included in the study were considered fit for either definitive chemoradiation or neoadjuvant therapy followed by surgery (CRTS). Because of differences in the patients' baseline medical and health characteristics that may have affected patient selection into different treatment groups, multivariate regression models were used to adjust the treatment effect for confounding variables of age, sex, ECOG performance status and histology.
A subset analysis was performed based on review of the pretreatment CT scan comparing only patients who were considered to have clearly resectable disease based on discrete or isolated mediastinal nodes and who could be resected by lobectomy. Patients with bulky or multistation N2 or those requiring or likely to require pneumonectomy or complex resections were excluded from the subset analysis.
Statistical methods
Continuous variables were described using medians, ranges and interquartile ranges, categorical variables using frequencies and proportions. Patients with and without surgery were compared on unordered categorical variables using Fisher's exact test, on ordered variables using the Cochran-Armitage Trend Test and on continuous variables using the Wilcoxon rank-sum non-parametric test.
Overall survival was measured from the date of diagnosis until the date of death, or the last follow-up. Patients alive at last followup were censored. Kaplan-Meier methodology and the log-rank test were used to plot survival and test for a difference between patients with and without surgery. The median follow-up was estimated using the reverse Kaplan-Meier estimator (Schemper and Smith [10] in 1996).
Time to recurrence (any location), time to local recurrence, time to loco-regional recurrence and time to distant recurrence were all measured from date of diagnosis, and death without the event of interest was treated as a competing risk event; patients with death from an unknown cause were censored at the last date that they were known to be free of recurrence since their recurrence status at date of death is uncertain. Plots of cumulative incidence functions estimating the probability of an event over time were generated and Gray's test was implemented to test for differences between patients with and without surgery.
In order to adjust for differences in patient and tumour characteristics (and hence the likelihood of having surgery) between patients with and without surgery, outcomes were also compared in regression models adjusting for age at diagnosis, cell type, ECOG, gender and smoking pack years. Because missing data on smoking pack years reduced our sample size for multivariate analyses, those analyses were also performed without adjusting for smoking pack years. Overall survival was compared using a Cox proportional hazard model, while time-to-recurrence outcomes were compared using the proportional subdistribution hazard regression model described by Fine and Gray (1999) [11] . Statistical significance was set to 0.05. The cmprsk package in the R 2.15.1 software was used for all competing risk analysis and the survival package was used to generate survival plots [12] [13] [14] . The SAS™ 9.3 TS Level 1M1 software was used for all remaining analysis.
RESULTS
There were 215 patients who met inclusion criteria, 104 patients were treated with neoadjuvant therapy followed by surgery (CRTS) and 111 with CRT without surgery. Patient characteristics and demographics are given in Table 1 . All patients were staged with CT scans. Positron Emission Tomography (PET) scans were not available during the majority of the study period. All surgical patients had histologically proven N2 disease. Surgical patients tended to be younger at diagnosis than non-surgical patients (median age at diagnosis 60.0 vs 62.2, P = 0.08) and were more likely to be female: 54 (51.9%) vs 42 (37.8%), P = 0.04). Smoking status varied between the treatment groups (P = 0.03). Patients who had surgery were more likely to be smoking at the time of diagnosis: 48 (46.2%) vs 35 (35.4%); but smoking pack years was similar between the two groups (median 35 vs 40, P = 0.27).
There was no significant difference in ECOG performance scores between the two groups (P = 0.69). All CRTS patients (104) and 105 of CRT patients were ECOG 0 or 1. Five of the CRT patients were ECOG 2 and the remaining patient was ECOG 3. Histology was also similar between the two groups (P = 0.60) (see Table 2 ).
The standard protocol for curative intent treatment for stage IIIA in our institution during the period of study was concurrent cisplatin and etoposide with 61 Gy radiation (RT) for patients treated with definitive CRT or neoadjuvant concurrent cisplatin and etoposide with 45 Gy followed by surgery. The majority of patients in both groups received cisplatin and etoposide [CRTS: 68 (65.4%) and CRT: 75 (67.6%)]. Ninety-one (87.5%) of CRTS patients received RT, with ninety (86.5%) planned to receive 45 Gy or more. All CRT patients received RT and all were planned for at least 61 Gy. Actual radiation delivered was a median 45 Gy, range 45-70 for the CRTS patients vs 61 Gy, range 9-70 (P < 0.0001) for the CRT patients. Lobectomy was performed in 83 (79.8%) of the CRTS patients while 21 (20.2%) had pneumonectomy.
CRTS patients had a lower median number of clinical N2 nodes based on pretreatment CT scans (4 vs 5); however, the difference was not statistically significant (P = 0.29).
Overall survival
The median follow-up is estimated at 10.5 years (95% CI: 8.8-11.6) for the CRTS patients compared with 9.0 years (95% CI: 6.9-10.6) for the CRT patients. Seventy-four (71.2%) surgical and 101 (91.0%) non-surgical patients died by the last follow-up. The Kaplan-Meier plot and log-rank test (P < 0.0001) suggest that surgical patients tend to have better survival outcomes. Median survival is estimated at 4.2 years (95% CI: 2.7, 7.2) for surgical patients versus 1.7 years (95% CI: 1.2-2.2) for non-surgical patients (see 1A ). When patients requiring pneumonectomy or who had tumours that were borderline for resection were excluded, overall survival remained significantly higher in the CRTS group compared with the CRT group (P = 0.005) (see Fig. 1B ).
The unadjusted hazard ratio (HR) also indicates a lower risk of death for surgical patients: HR = 0.43 (95% CI: 0.32-0.59, P < 0.0001). After adjusting for age at diagnosis, cell type, ECOG, gender and smoking pack years, surgery remains significant (HR: 0.45, 95% CI: 0.33-0.62, P < 0.0001). When adjusting for all covariates except smoking pack years, HR = 0.44, 95% CI: 0.32-0.60, P < 0.0001 (see Table 3 ).
There were 6 known postoperative deaths in the CRTS group (6.9% of the cohort when those with unknown cause of death are excluded) with 5 following pneumonectomy. Importantly, 4 occurred during the early years of our experience (1997, 1998 ). There only 1 further death following pneumonectomy in 2001 and 1 death following lobectomy in 2005. By the last follow-up, treatment-related deaths (excluding patients with unknown cause of death) in the CRT group were 2.3% (n = 2). Due to the low number of treatment-related deaths, a statistical test was not performed. Of patients who died in the follow-up, the cause of death was unknown in 17 (23%) of CRTS patients, and 24 (23.8%) of CRT patients while 58.1% of CRTS and 62.4% of CRT patients died of lung cancer (43/74 CRTS patients vs 63/101 CRT patients). Approximately, 3% in each group died of second primary lung cancer (see Table 3 ).
Recurrences (any location)
Fifty-seven (54.8%) surgical and 82 (73.9%) non-surgical patients recurred by the last follow-up. The cumulative incidence function and Gray's test (P < 0.0001) suggest that surgical patients tend to have longer times until first recurrence. The median time is estimated at 4.0 years (95% CI: 2.3, 8.9) for surgical patients and 1.1 years (95% CI: 0.9-1.7) for non-surgical patients (see Fig. 2 ). The unadjusted hazard ratio comparing surgical with non-surgical patients is 0.47 (95% CI: 0.34-0.65, P < 0.0001). After adjusting for age at diagnosis, cell type, ECOG, gender and smoking pack years, surgery is still significant (HR: 0.46, 95% CI: 0.32-0.64, P < 0.0001). When adjusting for all covariates except smoking pack years, HR = 0.45, 95% CI: 0.32-0.64, P < 0.0001 (see Table 3 ).
Local recurrences
Twenty-one (20.2%) surgical and 39 (35.1%) non-surgical patients recurred locally by the last follow-up. The cumulative incidence function and Gray's test (P = 0.003) suggest that surgical patients tend to have longer times until local recurrence. The median time to local recurrence was not reached in either group.
The unadjusted HR comparing surgical to non-surgical patients is 0.46 (95% CI: 0.27-0.77, P = 0.004). After adjusting for age at diagnosis, cell type, ECOG, gender and smoking pack years, surgery is still significant (HR: 0.50, 95% CI: 0.29-0.87, P = 0.013). When adjusting for all covariates except smoking pack years, HR = 0.49, 95% CI: 0.29-0.84, P = 0.010 (see Table 3 ).
Loco-regional recurrences
Thirty-five (33.7%) surgical and 57 (51.4%) non-surgical patients recurred locally and/or regionally by the last follow-up. The cumulative incidence function and Gray's test (P = 0.0005) suggest that surgical patients tend to have longer times until loco-regional recurrence.
The median time to loco-regional recurrence was not reached in the surgical group and is estimated at 3.3 years for non-surgical patients (95% CI: 1.8, upper limit could not be calculated).
The unadjusted HR comparing surgical with non-surgical patients is 0.49 (95% CI: 0.32-0.74, P = 0.0007). After adjusting for age at diagnosis, cell type, ECOG, gender and smoking pack years, surgery is still significant (HR 0.51, 95% CI: 0.33-0.78, P = 0.002); when smoking pack years is removed from the model, the results are unchanged (see Table 3 ).
Distant recurrences
Forty-four (42.3%) surgical and 55 (49.6%) non-surgical patients recurred distantly by last follow-up. The cumulative incidence function and Gray's test (P = 0.02) suggest that surgical patients tend to have longer times until distant recurrence. The median time to distant recurrence was only reached in the non-surgical group: 8.8 years (95% CI: 2.2-upper limit could not be calculated) (see Fig. 3 ). The unadjusted HR comparing surgical to non-surgical patients reaches significance: HR = 0.64 (95% CI: 0.43-0.94, P = 0.024). After adjusting for age at diagnosis, cell type, ECOG, gender and smoking pack years, surgery is still statistically significant (HR: 0.57, 95% CI: 0.38-0.87, P = 0.009). When adjusting for all covariates except smoking pack years, HR = 0.57, 95% CI: 0.37-0.87, P = 0.009 (see Table 3 ).
DISCUSSION
Our results show that when patients are carefully selected for neoadjuvant CRT followed by surgery, cancer-specific outcomes can be improved (OS, DFS). A treatment strategy that includes surgery may be an appropriate option but only for fit patients with good performance status and technically resectable disease. A multicentre randomized controlled trial provides the best evidence in comparing two different treatment strategies. However, because of the heterogeneity of stage III N2 disease, it is difficult to ensure that the burden of disease is similar between patients even within the same stage. This is a key confounder in comparing results of treatment for stage III N2 NSCLC. This is evident in the current study as CRT patients had more clinical N2 nodes than CRTS patients although the difference was not significant. By including patients who were fit enough to receive either definitive CRT or neoadjuvant therapy followed by surgery, we have excluded many patients with stage III N2 disease. In this study, 105 of 111 CRT patients were ECOG 0 or 1 just as the CRTS patients. In this way, we have attempted to reduce the selection bias that generally favours surgical treatment. Similarly, by reviewing the pretreatment CT scans to verify that patients were technically resectable, we have excluded those patients who were treated with curative intent CRT but who had surgically unresectable bulky or invasive disease.
Our results favour CRTS for patients with less extensive disease (i.e. those that could be resected by lobectomy) as well as those with more extensive disease including those who required pneumonectomy. Although the mortality of CRT followed by pneumonectomy was high in the early phase of our study, there was only 1 post-pneumonectomy death in the latter part of the study. Improvements in postoperative care, improved selection and technical experience may have all contributed to the improved postoperative survival in the latter part of the study.
Our results also suggest CRTS improves distant control, compared with those treated with CRT. Although these results support the hypothesis that surgery improves survival by removing microscopic disease that remains after CRT, thereby reducing distant metastases, our analysis was not designed to address this. These findings merit further study. In contrast, the intergroup 0139 trial, did not find any improvement in distant recurrence in the surgery arm of the trial (37.1 vs 41.8%) [7] .
Based on our results, we believe that surgery is an important component of the treatment algorithm for patients with stage IIIA N2 disease who have good performance status and technically resectable disease. Also we found, after our early experience, we could safely resect patients after neoadjuvant therapy even if a pneumonectomy was required.
Restaging with CT scans but not invasive mediastinal restaging was performed after neoadjuvant therapy in the CRTS patients in this study. If the disease remained technically resectable with no evidence of progression, patients went to surgery. Radiographic response was not used as prior experience had demonstrated that after CRT, radiographic appearance does not correlate with pathological downstaging [15] . Although patients with complete pathological response or at least sterilization of the mediastinum appear to have the best survival outcomes after neoadjuvant therapy, in our study even those patients who had partial responses appeared to benefit from neoadjuvant therapy followed by surgery. Similar results have been reported previously even in patients requiring pneumonectomy [7, 16] .
The limitations of this study include the retrospective study design, lack of randomization and lack of comorbidity data and single institution experience. Single institution experience may limit the generalizability of our data but may also be a strength of our study in that all surgeons had experience in operating on stage IIIA (N2) disease after CRT. ECOG performance status was used as a surrogate for comorbidity. The ECOG score has been shown to be a predictive of a patient's ability to tolerate intensive therapy, and may even be superior to comorbidity scores as it is a functional assessment rather than just a summary of diseases. We have attempted to address the lack of randomization by adjusting for relevant factors using multivariate regression models.
Based on our experience, we continue to offer neoadjuvant therapy followed by surgery to select patients with stage IIIA N2 NSCLC who have technically resectable disease and good performance status (ECOG 0-1). Formal lymphadenectomy is an essential component of our resection protocol. For patients with bulky disease that are considered borderline for resection, we recommend higher radiation doses (61 Gy) as this is more likely to sterilize the mediastinum and prevents interrupted radiation treatment if the patient ultimately does not proceed to surgery. We have found as have others that this approach appears to be safe and well-tolerated [17] . Although we are more reluctant to recommend surgery if the patient requires a pneumonectomy, this does not preclude surgery.
In conclusion, our results suggest that surgery should be considered in the treatment algorithm for patients with stage IIIA N2 NSCLC. Surgical resection following neoadjuvant therapy, may improve survival in select patients with stage IIIA N2 NSCLC who have good performance status, technically resectable disease. In experienced centres, surgery after CRT may be safely performed without significant mortality, even if pneumonectomy is required.
APPENDIX. CONFERENCE DISCUSSION
Dr W. Weder (Zurich, Switzerland): I was wondering why you applied chemoradiation and not chemotherapy alone as induction? It has never been shown that the addition of radiation in a neoadjuvant setting for N2 disease, nor in the adjuvant setting, improves survival. In fact, the Swiss Cancer Research Group presented a randomized study at the ASCO meeting showing that the addition of radiation to chemotherapy is not improving overall survival nor disease-free survival. So why not chemotherapy alone as induction for N2 disease?
Dr Darling: This is our institutional protocol based on the Intergroup 0139 trial. Because we participated in that trial, we continued with that same protocol after the trial was closed. We believe that our radiation improves the mediastinal downstaging, and we did not find that it increased morbidity or mortality. So we continued to use it as an institutional preference.
Dr Weder: But in fact there are no data in the literature showing that the survival is any better; in fact, it is to the contrary. Did you look at the study presented at ASCO? Dr Darling: That was recently. Obviously we did not have that data when we did the study.
Dr A. Turna (Istanbul, Turkey): I think this study will help to redefine the role of neoadjuvant chemoradiotherapy in the future. I would like to ask two questions. Why didn't you use histologically or pathologically proven N2 disease as an exclusion criterion after neoadjuvant therapy as was done in previous studies, and why didn't you use progression as an exclusion criterion? Also, how many patients were excluded after their neoadjuvant chemoradiotherapy?
Dr Darling: We did not use persistent N2 as an exclusion criterion, largely because we didn't believe that it should be, so therefore there were no patients excluded based on persistent N2. Patients were excluded if they had progression of their disease at other sites in terms of distant recurrence or metastatic disease, but not in their mediastinal disease.
Dr Turna: Exclusion? Dr Darling: They were not excluded. Dr C. Gebitekin (Bursa, Turkey): What was the complete response rate of your surgical group? We had a large group of cases, but the problem is the complete responders. We are having difficulty in distinguishing those patients that will have benefit from surgery, or just to follow-up.
Dr Darling: Our complete response rate was 29%. We found, however, that there is no way to really identify those patients. Radiographically on CT they may still have a residual mass in their primary disease, they may even have residual visible nodes, but that does not predict incomplete response. At the time those data were collected, we were not doing routine PET scanning, we were just starting to do PET scanning. We have not found subsequently that PET is the complete answer, however. But at the time this study was done, we did not have PET available.
We made a decision up front that we were going to operate on these patients. So we decided at the very beginning whether they were operable or not. That was how we approached our patients. In the randomized trial, of course, it was different. They were assigned by random analysis. But once the trial was completed or the accrual was completed, we continued to treat patients on the same chemoradiation/surgery protocol, and so the decision was made up front at tumour board that the patient was operable. So whether they appeared to have a radiographic response or not, we proceeded with resection.
Dr Gebiteken: Do you have any policy at present if the tumour requires pneumonectomy?
Dr Darling: Immediately after publication of the trial, people were less likely to do pneumonectomy. However, when we reviewed our results that we had published previously, we found we had no deaths from pneumonectomy after that initial experience, and so we did not exclude patients from surgery if they required a pneumonectomy. I will say, however, that we were less likely to consider them for surgery and they were less likely to be referred for surgery.
Dr D. Rice (Houston, TX, USA): Did you look at responders versus nonresponders radiographically and look at RECIST criteria and such to see what the survival was in the non-responder group compared to the definitive group?
Dr Darling: We did not look at RECIST criteria, we did not look at radiographic response, and, again, that was based on our prior experience with the Pancoast trial where we would see patients with large residual masses and yet they would have had a complete pathologic response. So we didn't feel it was useful.
Dr J. Kuzdzal (Krakow, Poland): In the light of the data you presented, and also the data from the Intergroup trial, showing that patients benefit from surgery even if there is persistent N2 disease, do you think there is still a place for surgical invasive staging in this group of patients? Dr Darling: We do believe in that even though the data I presented do not necessarily support it. Our strategy now is to do EBUS staging prior to induction treatment. So confirm the N2 disease, rule out N3 disease by EBUS-TBNA, then they get their chemoradiation, and then we would restage them by mediastinoscopy. And I would also add that we have increased the radiation dose. So we are now giving a definitive radiation dose of 60 Gy, not just 45.
Dr Kuzdzal: So if there is persistent N2 disease confirmed after chemoradiation, you would deny the surgery and only do additional radiation?
Dr Darling: Instead of giving the 45 Gy induction dose of radiation, we are giving 60. So that if we decide not to proceed with surgery, we haven't compromised their definitive chemoradiation. If they have persistent N2 disease, it is discussed at the multidisciplinary tumour board and a decision is made there.
It is largely based on whether we think the disease is technically resectable, if they have single station disease. If they have, for example, a high station 2R or 2L node, we would not usually go on and resect that patient. However, if they have a limited station 4 disease or station 7, we would often go on but not necessarily always. We are using the restaging more than we used to.
